These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 32116096)
1. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease. O'Hara DM; Kalia SK; Kalia LV Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096 [TBL] [Abstract][Full Text] [Related]
2. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome. Wang R; Sun H; Ren H; Wang G Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494 [TBL] [Abstract][Full Text] [Related]
3. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease. Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273 [TBL] [Abstract][Full Text] [Related]
4. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains. Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884 [TBL] [Abstract][Full Text] [Related]
5. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Roberts RF; Wade-Martins R; Alegre-Abarrategui J Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184 [TBL] [Abstract][Full Text] [Related]
6. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933 [TBL] [Abstract][Full Text] [Related]
7. The misfolding mystery: α-synuclein and the pathogenesis of Parkinson's disease. Negi S; Khurana N; Duggal N Neurochem Int; 2024 Jul; 177():105760. PubMed ID: 38723900 [TBL] [Abstract][Full Text] [Related]
8. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology. Hayakawa H; Nakatani R; Ikenaka K; Aguirre C; Choong CJ; Tsuda H; Nagano S; Koike M; Ikeuchi T; Hasegawa M; Papa SM; Nagai Y; Mochizuki H; Baba K Mov Disord; 2020 Feb; 35(2):256-267. PubMed ID: 31643109 [TBL] [Abstract][Full Text] [Related]
9. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients. Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109 [TBL] [Abstract][Full Text] [Related]
10. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies. Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153 [TBL] [Abstract][Full Text] [Related]
11. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts. Teil M; Arotcarena ML; Faggiani E; Laferriere F; Bezard E; Dehay B Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138193 [TBL] [Abstract][Full Text] [Related]
12. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease? Kanaan NM; Manfredsson FP J Parkinsons Dis; 2012; 2(4):249-67. PubMed ID: 23938255 [TBL] [Abstract][Full Text] [Related]
13. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease. Barrenschee M; Zorenkov D; Böttner M; Lange C; Cossais F; Scharf AB; Deuschl G; Schneider SA; Ellrichmann M; Fritscher-Ravens A; Wedel T Acta Neuropathol Commun; 2017 Jan; 5(1):1. PubMed ID: 28057070 [TBL] [Abstract][Full Text] [Related]
14. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897 [TBL] [Abstract][Full Text] [Related]
15. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. Mehra S; Sahay S; Maji SK Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581 [TBL] [Abstract][Full Text] [Related]
16. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations. Sahay S; Ghosh D; Singh PK; Maji SK Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727 [TBL] [Abstract][Full Text] [Related]
17. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment. Kalsoom I; Wang Y; Li B; Wen H Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991 [TBL] [Abstract][Full Text] [Related]
18. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202 [TBL] [Abstract][Full Text] [Related]
19. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease. Xu S; Chan P Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626 [TBL] [Abstract][Full Text] [Related]
20. Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis. Mukherjee S; Sakunthala A; Gadhe L; Poudyal M; Sawner AS; Kadu P; Maji SK J Mol Biol; 2023 Jan; 435(1):167713. PubMed ID: 35787838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]